Benitec Biopharma Ltd Stock Probability of Future Stock Price Finishing Under 11.96

BNTC Stock  USD 12.00  0.42  3.63%   
Benitec Biopharma's future price is the expected price of Benitec Biopharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Benitec Biopharma Ltd performance during a given time horizon utilizing its historical volatility. Check out Benitec Biopharma Backtesting, Benitec Biopharma Valuation, Benitec Biopharma Correlation, Benitec Biopharma Hype Analysis, Benitec Biopharma Volatility, Benitec Biopharma History as well as Benitec Biopharma Performance.
  
As of December 27, 2024, Price To Sales Ratio is expected to decline to 75.45. In addition to that, Price Earnings Ratio is expected to decline to -1.42. Please specify Benitec Biopharma's target price for which you would like Benitec Biopharma odds to be computed.

Benitec Biopharma Target Price Odds to finish below 11.96

The tendency of Benitec Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to drop to $ 11.96  or more in 90 days
 12.00 90 days 11.96 
about 92.05
Based on a normal probability distribution, the odds of Benitec Biopharma to drop to $ 11.96  or more in 90 days from now is about 92.05 (This Benitec Biopharma Ltd probability density function shows the probability of Benitec Stock to fall within a particular range of prices over 90 days) . Probability of Benitec Biopharma price to stay between $ 11.96  and its current price of $12.0 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days Benitec Biopharma Ltd has a beta of -0.2 suggesting as returns on the benchmark increase, returns on holding Benitec Biopharma are expected to decrease at a much lower rate. During a bear market, however, Benitec Biopharma Ltd is likely to outperform the market. Additionally Benitec Biopharma Ltd has an alpha of 0.5855, implying that it can generate a 0.59 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Benitec Biopharma Price Density   
       Price  

Predictive Modules for Benitec Biopharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Benitec Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Benitec Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
6.4511.9417.43
Details
Intrinsic
Valuation
LowRealHigh
2.548.0313.52
Details
7 Analysts
Consensus
LowTargetHigh
5.466.006.66
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-5.92-2.35-0.35
Details

Benitec Biopharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Benitec Biopharma is not an exception. The market had few large corrections towards the Benitec Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Benitec Biopharma Ltd, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Benitec Biopharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.59
β
Beta against Dow Jones-0.2
σ
Overall volatility
0.97
Ir
Information ratio 0.1

Benitec Biopharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Benitec Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Benitec Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Benitec Biopharma is way too risky over 90 days horizon
Benitec Biopharma appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 216 K. Net Loss for the year was (21.75 M) with profit before overhead, payroll, taxes, and interest of 75 K.
Benitec Biopharma Ltd currently holds about 4.06 M in cash with (19.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5.
Benitec Biopharma has a poor financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Suvretta Capital Management, Llc of 3142 shares of Benitec Biopharma at 10.98 subject to Rule 16b-3

Benitec Biopharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Benitec Stock often depends not only on the future outlook of the current and potential Benitec Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Benitec Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding4.1 M
Cash And Short Term Investments50.9 M

Benitec Biopharma Technical Analysis

Benitec Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Benitec Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Benitec Biopharma Ltd. In general, you should focus on analyzing Benitec Stock price patterns and their correlations with different microeconomic environments and drivers.

Benitec Biopharma Predictive Forecast Models

Benitec Biopharma's time-series forecasting models is one of many Benitec Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Benitec Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Benitec Biopharma

Checking the ongoing alerts about Benitec Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Benitec Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Benitec Biopharma is way too risky over 90 days horizon
Benitec Biopharma appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 216 K. Net Loss for the year was (21.75 M) with profit before overhead, payroll, taxes, and interest of 75 K.
Benitec Biopharma Ltd currently holds about 4.06 M in cash with (19.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5.
Benitec Biopharma has a poor financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Suvretta Capital Management, Llc of 3142 shares of Benitec Biopharma at 10.98 subject to Rule 16b-3
When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.51)
Revenue Per Share
0.003
Quarterly Revenue Growth
0.125
Return On Assets
(0.50)
Return On Equity
(0.92)
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.